Latest Content

Former NFL linebacker Chris Draft honors his late wife Keasha by advocating for lung cancer research and equitable access to care.

Four breast cancer treatments are awaiting FDA decisions, with two due before the end of 2026. Here's what's under review, what the data show and what it means.

T-cell engagers and other cellular therapies could help the immune system recognize and target lung cancer, including small cell lung cancer.

NEJM-published phase 1/2 data show RASONQUE achieved a 42% response rate and 89% disease control in RAS mutant metastatic lung cancer.

In the phase 3 CERVINO trial, etentamig improved response rates and progression-free survival compared with standard therapies in patients with relapsed/refractory multiple myeloma.

Gail Fackler reflected on her husband Jim’s stage 4 small cell lung cancer diagnosis, the uncertainty they faced and the hope they found through a clinical trial.

Dr. Jenni Sheng discussed weight management after breast cancer, when medication may be considered and why survivorship care goes beyond cancer surveillance.

Brynn Forlizzi was just 15 when diagnosed with ovarian cancer. She shares 10 things that helped her navigate treatment while staying connected to her teenage life.

Lung cancer patient and her father, a cancer survivor and caregiver, share how community, hope and self-advocacy helped them through treatment.

Diagnosed with stage 2B lung cancer after a screening, Vicky found community and a new purpose through lung cancer advocacy.

T-cell engagers and antibody-drug conjugates are expanding the SCLC treatment landscape as researchers focus on improving responses and overcoming resistance.

Rob Lowe joins CURE Talks Cancer to share his grandmother's breast cancer journey, including the clinical trial that helped prolong her life after she was twice told to get her affairs in order.

Karyopharm submitted an FDA application seeking accelerated approval for XPOVIO plus ruxolitinib for patients with myelofibrosis.